Get started
Author

Jessica Mann

Observed names: J. Mann, J. Tift Mann, J.T. Mann
Observed institutions: F. Hoffmann-La Roche AG, WakeMed
OpenAlex ID: A5109177954
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non–ST-Segment Elevation Myocardial Infarction
2013 · Jean-Claude Tardif, Jean-François Tanguay, et al. · Journal of the American College of Cardiology · 206
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention
2003 · S.R. Steinhubl, P.B. Berger, et al. · ACC Current Journal Review · 191
Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial
2016 · Barbara E. Stähli, Catherine Gebhard, et al. · Journal of the American Heart Association · 81
PDF
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery
2016 · Barbara E. Stähli, Jean-Claude Tardif, et al. · Journal of the American College of Cardiology · 46
PDF
Increased arterial inflammation in individuals with stage 3 chronic kidney disease
2015 · Richard A. P. Takx, Megan H. MacNabb, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 19
Cardiovascular Drug Discovery: A Perspective from a Research-Based Pharmaceutical Company
2014 · G. Gromo, J. Mann, et al. · Cold Spring Harbor Perspectives in Medicine · 19
PDF
Clopidogrel and Percutaneous Coronary Interventions—Reply
2003 · Steven R. Steinhubl, Peter B. Berger, et al. · JAMA
Works count: 7
Citation count: 562
H-index: 6
I10-index: 6
Year
Topic
Type